Pancreatic Cancer Research

ResearcherHarvard UniversityNo recent work listed

Annan Yang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6750-0304; OpenAlex author ID A5070552049. Sources: OpenAlex.

Their work

Papers
9
Trials
0
Grants
0
Labs led
0
Collaborators
58
Papers, trials and grants by year

2014: 2 papers · 2015: none · 2016: none · 2017: none · 2018: 2 papers · 2019: none · 2020: none · 2021: 1 paper · 2022: 2 papers · 2023: 2 papers

Papers 9

  1. Transforming Growth Factor-β Blockade in Pancreatic Cancer Enhances Sensitivity to Combination Chemotherapy. Co-author DOI 10.1053/j.gastro.2023.05.038↗
  2. Spatially Resolved Single-Cell Assessment of Pancreatic Cancer Expression Subtypes Reveals Co-expressor Phenotypes and Extensive Intratumoral Heterogeneity. Co-author DOI 10.1158/0008-5472.can-22-3050↗
  3. NCOA4-Mediated Ferritinophagy Is a Pancreatic Cancer Dependency via Maintenance of Iron Bioavailability for Iron-Sulfur Cluster Proteins. Co-author DOI 10.1158/2159-8290.cd-22-0043↗
  4. Coordinated Transcriptional and Catabolic Programs Support Iron-Dependent Adaptation to RAS-MAPK Pathway Inhibition in Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-22-0044↗
  5. SMAD4 represses FOSL1 expression and pancreatic cancer metastatic colonization. Co-author DOI 10.1016/j.celrep.2021.109443↗
  6. Oncogenic KRAS supports pancreatic cancer through regulation of nucleotide synthesis. Co-author DOI 10.1038/s41467-018-07472-8↗
  7. Autophagy Sustains Pancreatic Cancer Growth through Both Cell-Autonomous and Nonautonomous Mechanisms. Co-author DOI 10.1158/2159-8290.cd-17-0952↗
  8. Elevation of circulating branched-chain amino acids is an early event in human pancreatic adenocarcinoma development. Co-author DOI 10.1038/nm.3686↗
  9. Inhibition of autophagy attenuates pancreatic cancer growth independent of TP53/TRP53 status. Co-author DOI 10.4161/auto.29961↗

Closest collaborators

The 25 strongest of 58 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Andrew J. Aguirre · 5 shared papers, 2021–2023 · strength 0.59
  2. Joseph Douglas Mancias · 3 shared papers, 2022–2023 · strength 0.35
  3. Alec C. Kimmelman · 4 shared papers, 2014–2018 · strength 0.27
  4. Srivatsan Raghavan · 2 shared papers, 2023 · strength 0.26
  5. Jonathan Andrew Nowak · 2 shared papers, 2022–2023 · strength 0.23
  6. William C. Hahn · 2 shared papers, 2021–2023 · strength 0.21
  7. Douglas E. Biancur · 2 shared papers, 2018–2022 · strength 0.19
  8. Naiara Santana-Codina · 2 shared papers, 2018–2022 · strength 0.19
  9. Michael Lawrence Dougan · 1 shared paper, 2023 · strength 0.14
  10. Qiang Li · 1 shared paper, 2023 · strength 0.14
  11. Viviana Cremasco · 1 shared paper, 2023 · strength 0.14
  12. Victoire Cardot‐Ruffino · 1 shared paper, 2023 · strength 0.14
  13. Megan T. Hoffman · 1 shared paper, 2023 · strength 0.14
  14. Lestat R. Ali · 1 shared paper, 2023 · strength 0.14
  15. Marc R. Pelletier · 1 shared paper, 2023 · strength 0.14
  16. Stephanie K. Dougan · 1 shared paper, 2023 · strength 0.14
  17. Chen Yuan · 2 shared papers, 2014–2023 · strength 0.14
  18. Douglas Adam Rubinson · 2 shared papers, 2014–2023 · strength 0.14
  19. Brian Matthew Wolpin · 2 shared papers, 2014–2023 · strength 0.14
  20. Anthony C. Venida · 1 shared paper, 2022 · strength 0.12
  21. Gina M. DeNicola · 1 shared paper, 2022 · strength 0.12
  22. Mirunalini Ravichandran · 1 shared paper, 2022 · strength 0.12
  23. Gilles Rademaker · 1 shared paper, 2022 · strength 0.12
  24. Rushika Miriam Perera · 1 shared paper, 2022 · strength 0.12
  25. Harshabad Singh · 1 shared paper, 2023 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.